Clinical Trials
2 trialsNCT04023331 2025-09-16
67Cu-SARTATEā¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
Clarity Pharmaceuticals Ltd
Phase 1/2 Terminated
NCT03936426 2020-04-20
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEā¢
Clarity Pharmaceuticals Ltd
Phase 1/2 Completed